REMEGEN (09995) Signs Exclusive Licensing Agreement with AbbVie for RC148

Stock News01-12

REMEGEN (09995) announced that on January 12, 2026, the company entered into an exclusive licensing agreement with AbbVie Group Holding Company (AbbVie) for RC148. RC148 is a novel bispecific antibody drug targeting PD-1/VEGF developed by the company. Pursuant to the agreement, AbbVie will obtain exclusive rights for the development, production, and commercialization of RC148 in regions outside Greater China. Following the effectiveness of the agreement upon receiving relevant regulatory approvals, the company will receive an upfront payment of $650 million and will be eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments, in addition to tiered double-digit royalty fees based on net sales outside Greater China. The milestone payments stipulated in the agreement are contingent upon meeting certain conditions, and the final amount of milestone payments achievable by the company remains uncertain.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117696241?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 20:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117696241","market":"nz","top_or_hot":-1,"title":"REMEGEN (09995) Signs Exclusive Licensing Agreement with AbbVie for RC148","media":"Stock News","content":"<p>REMEGEN (09995) announced that on January 12, 2026, the company entered into an exclusive licensing agreement with AbbVie Group Holding Company (AbbVie) for RC148. RC148 is a novel bispecific antibody drug targeting PD-1/VEGF developed by the company. Pursuant to the agreement, AbbVie will obtain exclusive rights for the development, production, and commercialization of RC148 in regions outside Greater China. Following the effectiveness of the agreement upon receiving relevant regulatory approvals, the company will receive an upfront payment of $650 million and will be eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments, in addition to tiered double-digit royalty fees based on net sales outside Greater China. The milestone payments stipulated in the agreement are contingent upon meeting certain conditions, and the final amount of milestone payments achievable by the company remains uncertain.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>REMEGEN (09995) Signs Exclusive Licensing Agreement with AbbVie for RC148</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nREMEGEN (09995) Signs Exclusive Licensing Agreement with AbbVie for RC148\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-12 20:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN (09995) announced that on January 12, 2026, the company entered into an exclusive licensing agreement with AbbVie Group Holding Company (AbbVie) for RC148. RC148 is a novel bispecific antibody drug targeting PD-1/VEGF developed by the company. Pursuant to the agreement, AbbVie will obtain exclusive rights for the development, production, and commercialization of RC148 in regions outside Greater China. Following the effectiveness of the agreement upon receiving relevant regulatory approvals, the company will receive an upfront payment of $650 million and will be eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments, in addition to tiered double-digit royalty fees based on net sales outside Greater China. The milestone payments stipulated in the agreement are contingent upon meeting certain conditions, and the final amount of milestone payments achievable by the company remains uncertain.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1117696241","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117696241","pubTimestamp":1768222577,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"REMEGEN (09995) announced that on January 12, 2026, the company entered into an exclusive licensing agreement with AbbVie Group Holding Company (AbbVie) for RC148. RC148 is a novel bispecific...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688331":"荣昌生物","BK1574":"生物医药B类股","09995":"荣昌生物","BK1583":"高瓴概念","BK0239":"医药制造","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK1161":"生物科技"},"translate_title":"瑞美健(09995)与艾伯维签署RC148独家授权协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1,"09995":1},"content_text":"REMEGEN (09995) announced that on January 12, 2026, the company entered into an exclusive licensing agreement with AbbVie Group Holding Company (AbbVie) for RC148. RC148 is a novel bispecific antibody drug targeting PD-1/VEGF developed by the company. Pursuant to the agreement, AbbVie will obtain exclusive rights for the development, production, and commercialization of RC148 in regions outside Greater China. Following the effectiveness of the agreement upon receiving relevant regulatory approvals, the company will receive an upfront payment of $650 million and will be eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments, in addition to tiered double-digit royalty fees based on net sales outside Greater China. The milestone payments stipulated in the agreement are contingent upon meeting certain conditions, and the final amount of milestone payments achievable by the company remains uncertain.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117696241","isCrawlerRequest":true}